Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.35 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.34 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.33 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4602287 | 1.00 | NOS2 (0.42) | NOS2NOS3NOS1LTA4HCA1 | |
| SCHEMBL4602597 | 0.94 | LTA4H (0.39) | NOS2NOS3NOS1LTA4HCA1 | |
| SCHEMBL4602594 | 0.94 | LTA4H (0.39) | NOS2NOS3NOS1LTA4HCA1 | |
| Hydrochloric Acid SCHEMBL5967458 | 0.93 | LTA4H (0.38) | NOS2NOS3NOS1LTA4HCA1 | |
| SCHEMBL2446304 | 0.88 | LTA4H (0.41) | NOS2NOS3NOS1LTA4HCA1 | |
| SCHEMBL4603026 | 0.88 | LTA4H (0.41) | NOS2NOS3NOS1LTA4HCA1 | |
| Hydrochloric Acid SCHEMBL2445583 | 0.86 | LTA4H (0.40) | LTA4HCA1CA2CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL2445581 | 0.86 | LTA4H (0.40) | LTA4HCA1CA2CHRM2CHRM4 | |
| SCHEMBL16330498 | 0.83 | ZDHHC7 (0.45) | NOS2NOS3NOS1LTA4HCA1 | |
| SCHEMBL9383516 | 0.83 | CA1 (0.43) | LTA4HCA1CA2ZDHHC7DDAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924568-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2008-05-28 | — | — | EP | disclosed |
| EP-1915351-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2008-04-30 | — | — | EP | disclosed |
| US-20070032502-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070032502-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070032502-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-02-08 | — | — | US | disclosed |
| WO-2007011623-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007011618-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007011618-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20070015774-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-20070015774-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-20070015774-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015774-A1 | Quinazoline derivatives useful in cancer treatment | TP53, TP53BP1, ACIN1 | NOS2 2571/4885NOS3 1034/4885NOS1 2160/4885 |
| US-20070032502-A1 | Quinazoline derivatives useful in cancer treatment | TP53, ACIN1, TP53BP1 | NOS2 2281/4885NOS3 898/4885NOS1 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.